Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Arisan Therapeutics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner, CLARK, AMY LYNN, who is the busiest examiner for the portfolio with 1 pending action. The prosecution is confined to 1 distinct art unit.
This highly concentrated profile means that the practitioner's strategy for the 1 pending office action is entirely dependent on CLARK, AMY LYNN. The focus on 1 distinct art unit indicates a specific technological niche within Biotechnology & Pharmaceuticals. Practitioners should analyze the specific allowance rates and common rejection types associated with CLARK, AMY LYNN to prepare for the 1 pending action. Without other pending matters to provide variety, the practitioner must ensure that the strategy is perfectly aligned with this 1 examiner's expectations. This 1 to 1 relationship between the pending action and the examiner requires a precise and examiner specific approach to move the portfolio forward.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.1% | +31.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17726096 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | CLARK, AMY LYNN | 30d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17726096 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | CLARK, AMY LYNN | 1628 | §103 | Final Rejection | 30d | Pending | Apr 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArisan Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Amy Lynn Clark has the most, with 1 of Arisan Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.